Article
Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.
Nature genetics - 1 Sept 2015
Fischer Ute, Forster Michael, Rinaldi Anna, Risch Thomas, Sungalee Stéphanie, Warnatz Hans-Jörg, Bornhauser Beat, Gombert Michael, Kratsch Christina, Stütz Adrian M, Sultan Marc, Tchinda Joelle, Worth Catherine L, Amstislavskiy Vyacheslav, Badarinarayan Nandini, Baruchel André, Bartram Thies, Basso Giuseppe, Canpolat Cengiz, Cario Gunnar, Cavé Hélène, Dakaj Dardane, Delorenzi Mauro, Dobay Maria Pamela, Eckert Cornelia, Ellinghaus Eva, Eugster Sabrina, Frismantas Viktoras, Ginzel Sebastian, Haas Oskar A, Heidenreich Olaf, Hemmrich-Stanisak Georg, Hezaveh Kebria, Höll Jessica I, Hornhardt Sabine, Husemann Peter, Kachroo Priyadarshini, Kratz Christian P, Te Kronnie Geertruy, Marovca Blerim, Niggli Felix, McHardy Alice C, Moorman Anthony V, Panzer-Grümayer Renate, Petersen Britt S, Raeder Benjamin, Ralser Meryem, Rosenstiel Philip, Schäfer Daniel, Schrappe Martin, Schreiber Stefan, Schütte Moritz, Stade Björn, Thiele Ralf, von der Weid Nicolas, Vora Ajay, Zaliova Marketa, Zhang Langhui, Zichner Thomas, Zimmermann Martin, Lehrach Hans, Borkhardt Arndt, Bourquin Jean-Pierre, Franke Andre, Korbel Jan O, Stanulla Martin, Yaspo Marie-Laure
Abstract excerpt
TCF3-HLF-positive acute lymphoblastic leukemia (ALL) is currently incurable. Using an integrated approach, we uncovered distinct mutation, gene expression and drug response profiles in TCF3-HLF-positive and treatment-responsive TCF3-PBX1-positive ALL. We identified recurrent intragenic deletions of PAX5 or VPREB1 in constellation with the fusion of TCF3 and HLF. Moreover somatic mutations in the non-translocated...
Read the complete abstract on PubMed